Our parent company China National Biotec Group (CNBG) is the 6th largest vaccine manufacturer in the world. CNBG has the capacity of manufacturing approximately 700 million doses of 50 various human vaccines (a year?)
Sino-Innovax is also committed to benefit people from all around the globe through our constant development of efficient and novel vaccines. Our Singapore pipeline includes Enterovirus 71 vaccine (inactivated), quadrivalent influenza vaccine (inactivated), varicella vaccine (live attenuated) and more.
The COVID-19 pandemic has underscored the importance of research and development in preparation for future pandemics. In Sino-Innovax, we focus on predicting new infectious landscapes and challenge the frontiers of vaccine science. We are open to collaboration with innovative and cutting-edge technologies and products which align with our strategic interest.
Plasma being the largest component in the human blood, helps individuals to stay healthy. Plasma-derived products are prepared from the separation of proteins in the human plasma and are vital in the treatment of autoimmune diseases. a. Human Immunoglobulin (pH4) for Intravenous Injection IVIG targets a wide range of autoimmune diseases […]